Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.
Guardado en:
Autores principales: | Alison Hirukawa, Harvey W. Smith, Dongmei Zuo, Catherine R. Dufour, Paul Savage, Nicholas Bertos, Radia M. Johnson, Tung Bui, Guillaume Bourque, Mark Basik, Vincent Giguère, Morag Park, William J. Muller |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
por: Peter W. Eide, et al.
Publicado: (2021) -
EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy
por: Julian C. Lui, et al.
Publicado: (2016) -
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
por: Geneviève Deblois, et al.
Publicado: (2016) -
Stroke subtype-dependent synapse elimination by reactive gliosis in mice
por: Xiaojing Shi, et al.
Publicado: (2021) -
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)